

## **SWIXX SIGNS CEE REGIONAL AGREEMENT WITH JAZZ PHARMACEUTICALS FOR VYXEOS® LIPOSOMAL**

**SWIXX ANNOUNCEMENT NO. 38**

**March 15<sup>th</sup>, 2021**

**Baar, Switzerland** – Swixx BioPharma AG of Baar, Switzerland announced today the signing of an exclusive distribution contract with Jazz Pharmaceuticals Ireland Limited of Dublin, a fully-owned subsidiary of Jazz Pharmaceuticals plc. Under the agreement, Jazz has appointed Swixx as exclusive distributor to import, use, market, sell and distribute Vyxeos® Liposomal 44mg/100mg powder for concentrate for solution for infusion (daunorubicin and cytarabine) in the EU territories of Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Romania, Slovakia, and Slovenia.

Vyxeos Liposomal is the first dual-drug advanced liposomal formulation of daunorubicin and cytarabine that is indicated for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Vyxeos Liposomal is the first chemotherapy in over 40 years to demonstrate a significant overall survival advantage versus the current conventional treatment, 7+3 chemotherapy (cytarabine/daunorubicin) in a Phase 3 study of adult patients, aged 60-75, with newly diagnosed high-risk/secondary AML.

“I am honoured to announce this pan-regional agreement with Jazz,” commented Swixx COO Dr. Dezso Marta. “Vyxeos Liposomal is an important breakthrough therapy in high-risk AML and will bring a new therapeutic option to Central and Eastern European physicians and their patients. Further, Vyxeos Liposomal is an excellent fit with Swixx’s fast-expanding oncology - haematology franchise. I am confident that with the assistance of Swixx’s excellent country organizations, working hand in hand with Jazz, we can swiftly create access for CEE patients to this new therapy. Indeed, it is my sincere hope that we can build, over time, a broader strategic partnership with Jazz, which is blessed with an exciting portfolio of innovative medicines in neurosciences, haematology-oncology and rare disease.”

### **About Swixx BioPharma AG**

Swixx operates fully owned subsidiaries across Central and Eastern Europe and Russia. With 600 employees and sales likely to exceed 270M Euros in 2021, Swixx has swiftly evolved into the largest and fastest-growing dedicated agent for biopharma and self-medication innovative companies in CEE. The company has gathered outstanding rare disease, oncology-haematology, specialty, and self-medication talent under one roof. For more information about Swixx, please visit: [www.swixxbiopharma.com](http://www.swixxbiopharma.com)

**Contact: Maja Boskovic, Public Affairs Officer, Swixx BioPharma A.G.**

Maja.Boskovic@swixxbiopharma.com Tel: +381 11 4426 321

**Note on Unsubscribing from Swixx Announcement Mailing List:** In accordance with the European Union’s GDPR (General Data Protection Regulation) provisos, should you wish to unsubscribe / opt out of our mailing list, please send to [Maja.Boskovic@swixxbiopharma.com](mailto:Maja.Boskovic@swixxbiopharma.com) a one-line message “Please unsubscribe me.”